DNMT3A and acute myeloid leukemia: In this context, our group (53) recently demonstrated that expression levels of DNMT3A mutations do not reflect disease status in AML, and that, distinct from NPM1 mutations, they characterize pre-leukemic populations persisting at the time of CR.